KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) Interest & Investment Income (2017 - 2022)

Sarepta Therapeutics has reported Interest & Investment Income over the past 9 years, most recently at $9.1 million for Q4 2022.

  • For Q4 2022, Interest & Investment Income rose 9506.32% year-over-year to $9.1 million; the TTM value through Dec 2022 reached $16.5 million, up 4557.63%, while the annual FY2023 figure was $36.3 million, 119.9% up from the prior year.
  • Interest & Investment Income for Q4 2022 was $9.1 million at Sarepta Therapeutics, up from $4.8 million in the prior quarter.
  • Over five years, Interest & Investment Income peaked at $9.1 million in Q4 2022 and troughed at -$7.0 million in Q3 2018.
  • A 5-year average of $403400.0 and a median of $160500.0 in 2021 define the central range for Interest & Investment Income.
  • Biggest five-year swings in Interest & Investment Income: plummeted 3886.96% in 2018 and later surged 9506.32% in 2022.
  • Year by year, Interest & Investment Income stood at -$2.3 million in 2018, then skyrocketed by 164.04% to $1.5 million in 2019, then crashed by 95.2% to $71000.0 in 2020, then skyrocketed by 33.8% to $95000.0 in 2021, then surged by 9506.32% to $9.1 million in 2022.
  • Business Quant data shows Interest & Investment Income for SRPT at $9.1 million in Q4 2022, $4.8 million in Q3 2022, and $2.4 million in Q2 2022.